Pei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pei Yang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Zhiyan Sun
Department of Gamma Knife, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
8 shared publicationsRui Tao
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
7 shared publications- Xiaoyan Zhao
School of Automation and Electrical Engineering, University of Science and Technology Beijing, Beijing, China
7 shared publications Minghui Du
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
6 shared publicationsXianhao Wu
School of Automation and Electrical Engineering, University of Science and Technology Beijing, Beijing, China
6 shared publicationsZhaohui Zhang
School of Automation and Electrical Engineering, University of Science and Technology Beijing, Beijing, China
6 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Laser Interstitial Thermal Therapy Followed by Ultra Early Temozolomide for First Recurrent IDH Wild Type Glioblastoma: A Comparative Cohort Study With Prospective Enrolment and Retrospective Controls
Background: Evidence for laser interstitial thermal therapy (LITT) followed by ultra-early temozolomide at first recurrence of IDH-wild-type glioblastoma is limited. We assessed survival relative to nonsurgical management while accounting for measured treatment-selection differences. Methods: This single-centre comparative cohort study combined a prospective phase II LITT cohort (NCT05663125) with retrospective controls at Beijing Tiantan Hospital, China, during 2018–2024. Eligible patients were aged 18–75 years, had a first recurrence, and had Karnofsky Performance Status of at least 60. The complete-case cohort included 90 patients: ten receiving LITT, 43 surgery, and 37 nonsurgical management. Temozolomide began on postoperative day 2 after LITT. The primary overall survival comparison used LITT-focused propensity-score weighting targeting the average treatment effect on the treated. Secondary surgery analyses used overlap weighting; subgroup and PET/MR analyses were exploratory. Confidence intervals for 12-month restricted mean survival time differences were estimated with 10 000 stratified nonparametric bootstrap resamples, repeating propensity-score weighting within each resample. Findings: LITT plus ultra-early temozolomide was associated with longer survival than nonsurgical management (hazard ratio 0·31 [95% CI 0·13–0·77]; p=0·012). Twelve-month restricted mean survival was 305·95 versus 221·00 days, a difference of 84·95 days (percentile bootstrap 95% CI 4·67–173·28). The secondary surgery comparison yielded a hazard ratio of 0·39 (0·19–0·80; p=0·010) and a 12-month restricted mean survival difference of 54·54 days (−25·68 to 128·79). Insufficient common support precluded a reliable direct LITT–surgery comparison. PET/MR coverage was assessable in nine patients, with no statistically significant metric. Interpretation: LITT followed by ultra-early temozolomide was associated with longer survival in patients resembling the LITT cohort. The small, non-randomised study cannot establish causality or separate the contributions of LITT and temozolomide timing. Prospective comparative validation is needed.
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLaser Interstitial Thermal Therapy Followed by Ultra Early Temozolomide for First Recurrent IDH Wild Type Glioblastoma: A Comparative Cohort Study With Prospective Enrolment and Retrospective Controls
Background: Evidence for laser interstitial thermal therapy (LITT) followed by ultra-early temozolomide at first recurrence of IDH-wild-type glioblastoma is limited. We assessed survival relative to nonsurgical management while accounting for measured treatment-selection differences. Methods: This single-centre comparative cohort study combined a prospective phase II LITT cohort (NCT05663125) with retrospective controls at Beijing Tiantan Hospital, China, during 2018–2024. Eligible patients were aged 18–75 years, had a first recurrence, and had Karnofsky Performance Status of at least 60. The complete-case cohort included 90 patients: ten receiving LITT, 43 surgery, and 37 nonsurgical management. Temozolomide began on postoperative day 2 after LITT. The primary overall survival comparison used LITT-focused propensity-score weighting targeting the average treatment effect on the treated. Secondary surgery analyses used overlap weighting; subgroup and PET/MR analyses were exploratory. Confidence intervals for 12-month restricted mean survival time differences were estimated with 10 000 stratified nonparametric bootstrap resamples, repeating propensity-score weighting within each resample. Findings: LITT plus ultra-early temozolomide was associated with longer survival than nonsurgical management (hazard ratio 0·31 [95% CI 0·13–0·77]; p=0·012). Twelve-month restricted mean survival was 305·95 versus 221·00 days, a difference of 84·95 days (percentile bootstrap 95% CI 4·67–173·28). The secondary surgery comparison yielded a hazard ratio of 0·39 (0·19–0·80; p=0·010) and a 12-month restricted mean survival difference of 54·54 days (−25·68 to 128·79). Insufficient common support precluded a reliable direct LITT–surgery comparison. PET/MR coverage was assessable in nine patients, with no statistically significant metric. Interpretation: LITT followed by ultra-early temozolomide was associated with longer survival in patients resembling the LITT cohort. The small, non-randomised study cannot establish causality or separate the contributions of LITT and temozolomide timing. Prospective comparative validation is needed.
- Open Access
- 2 September 2026
- Published by Springer Nature in npj Biomedical Innovations
- Vol. 3 (1) , 54
Terahertz-based prognostic framework for glioma: from spectral features to patient-level prognostic assessment
- 2 September 2026
- Published by Springer Nature in npj Biomedical Innovations
- Vol. 3 (1) , 54
Open AccessTerahertz-based prognostic framework for glioma: from spectral features to patient-level prognostic assessment
- Open Access
- 30 August 2026
- Published by MDPI AG in Biosensors
- Vol. 16 (9) , 476
Low-Cost Self-Driven Liquid Biosensor Based on Metamaterials for Glioblastoma-Related Sample Detection
A self-driven terahertz metamaterial liquid biosensor composed of channel-structured metamaterials and a quartz microcavity is proposed for glioblastoma sample detection. The device transports liquid samples via capillary force. The permittivity (εeff) of liquid suspensions is comprehensively analyzed to provide theoretical support for the detection. For suspensions with the same contents, εeff decreases with increasing concentration, while under the same concentration condition, εeff decreases as particle size grows. An electric dipole resonance is excited at ~1.54 THz with theoretical sensitivity ≥ 242 GHz/RIU (where RIU denotes refractive index unit). For the same type of cell discrimination, the frequencies of the biosensor’s feature peaks shift from ~1.14, ~1.18, and ~1.20 THz with the rise in cell concentration of glioblastoma stem cell (GSC) suspension from 4 × 105, 6 × 105 to 8 × 105 cells/mL, respectively. In addition, the GSC, U87 and U251—whose average diameters increase in that order—tested at the same concentration of 4 × 105 cells/mL lead to feature peak shifts from ~1.14, ~1.17, and ~1.20 THz. Clear THz differences exist between healthy and patient serum, with peaks at 1.18 and 1.19 THz. The sensor effectively distinguishes cell suspensions but has limited serum discrimination capacity. The sensor retains cell morphology, requires little pretreatment, and is low-cost and fast for rapid glioblastoma clinical screening.
- 30 August 2026
- Published by MDPI AG in Biosensors
- Vol. 16 (9) , 476
Open AccessLow-Cost Self-Driven Liquid Biosensor Based on Metamaterials for Glioblastoma-Related Sample Detection
A self-driven terahertz metamaterial liquid biosensor composed of channel-structured metamaterials and a quartz microcavity is proposed for glioblastoma sample detection. The device transports liquid samples via capillary force. The permittivity (εeff) of liquid suspensions is comprehensively analyzed to provide theoretical support for the detection. For suspensions with the same contents, εeff decreases with increasing concentration, while under the same concentration condition, εeff decreases as particle size grows. An electric dipole resonance is excited at ~1.54 THz with theoretical sensitivity ≥ 242 GHz/RIU (where RIU denotes refractive index unit). For the same type of cell discrimination, the frequencies of the biosensor’s feature peaks shift from ~1.14, ~1.18, and ~1.20 THz with the rise in cell concentration of glioblastoma stem cell (GSC) suspension from 4 × 105, 6 × 105 to 8 × 105 cells/mL, respectively. In addition, the GSC, U87 and U251—whose average diameters increase in that order—tested at the same concentration of 4 × 105 cells/mL lead to feature peak shifts from ~1.14, ~1.17, and ~1.20 THz. Clear THz differences exist between healthy and patient serum, with peaks at 1.18 and 1.19 THz. The sensor effectively distinguishes cell suspensions but has limited serum discrimination capacity. The sensor retains cell morphology, requires little pretreatment, and is low-cost and fast for rapid glioblastoma clinical screening.
- Open Access
- 5 August 2026
- Published by Elsevier in SSRN Electronic Journal
Prediction of TP53 Mutation Status in Glioma Based on Terahertz Spectral Data and DA-RMCNet Model
Glioma is the primary malignant tumor of the central nervous system and has a high mortality rate. TP53 is an important molecular marker in glioma, and its mutational status is closely associated with tumor malignancy and patient prognosis. To address the limitations of traditional molecular detection methods, such as long turnaround times, complex procedures, and difficulty in meeting intraoperative rapid diagnosis requirements, this paper proposes a TP53 mutation prediction method for glioma based on terahertz spectral data and a dual-attention residual multi-scale convolutional network (DA-RMCNet). Firstly, the collected terahertz absorption spectra of glioma tissues are preprocessed. Subsequently, a residual multi-scale convolutional network integrating a frequency attention mechanism and an SE (Squeeze-and-Excitation) channel attention mechanism is constructed to achieve synergistic enhancement of key spectral bands and important feature channels as well as multi-scale spectral feature extraction. Experimental results demonstrated that DA-RMCNet achieved a classification accuracy of 0.8636 and an AUC value of 0.9350 in the TP53 mutation prediction task, it is superior to traditional machine learning models.The results indicated that terahertz time-domain spectroscopy combined with deep learning methods were enable rapid prediction of TP53 mutation status in glioma, providing a technical approach for intraoperative molecular pathological diagnosis of glioma.
- 5 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrediction of TP53 Mutation Status in Glioma Based on Terahertz Spectral Data and DA-RMCNet Model
Glioma is the primary malignant tumor of the central nervous system and has a high mortality rate. TP53 is an important molecular marker in glioma, and its mutational status is closely associated with tumor malignancy and patient prognosis. To address the limitations of traditional molecular detection methods, such as long turnaround times, complex procedures, and difficulty in meeting intraoperative rapid diagnosis requirements, this paper proposes a TP53 mutation prediction method for glioma based on terahertz spectral data and a dual-attention residual multi-scale convolutional network (DA-RMCNet). Firstly, the collected terahertz absorption spectra of glioma tissues are preprocessed. Subsequently, a residual multi-scale convolutional network integrating a frequency attention mechanism and an SE (Squeeze-and-Excitation) channel attention mechanism is constructed to achieve synergistic enhancement of key spectral bands and important feature channels as well as multi-scale spectral feature extraction. Experimental results demonstrated that DA-RMCNet achieved a classification accuracy of 0.8636 and an AUC value of 0.9350 in the TP53 mutation prediction task, it is superior to traditional machine learning models.The results indicated that terahertz time-domain spectroscopy combined with deep learning methods were enable rapid prediction of TP53 mutation status in glioma, providing a technical approach for intraoperative molecular pathological diagnosis of glioma.
- Open Access
- 5 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Heat shock proteins related signature characterizes immune status and predicts prognosis of gliomas
Glioma classification is crucial for effective diagnosis and treatment. Heat Shock Proteins (HSPs) have been associated with tumor development and progression. In this study, we established a prognostic model for glioma based on Heat Shock Proteins-associated genes (HSPGs). Using the Cancer Genome Atlas (TCGA) cohorts and the Chinese Glioma Genome Atlas (CGGA), we identified a signature of 4 HSPGs as an independent prognostic factor for glioma. The risk model demonstrated excellent performance in both training and validation sets. Additionally, we developed a nomogram incorporating clinical parameters and the HSPGs signature to enhance prognostic prediction. Immunoenrichment analysis revealed a correlation between the risk score and the immunosuppressive status of glioma. In the functional assays, HSPA5 was identified as a key participant in several critical biological processes associated with glioma. Silencing HSPA5 expression may lead to the inhibition of glioma cell proliferation, migration, invasion and resistance to apoptosis. These findings present a novel classification for glioma prognosis with enhanced accuracy and offer valuable insights into the potential use of HSPGs as prognostic indicators for gliomas.
- 5 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessHeat shock proteins related signature characterizes immune status and predicts prognosis of gliomas
Glioma classification is crucial for effective diagnosis and treatment. Heat Shock Proteins (HSPs) have been associated with tumor development and progression. In this study, we established a prognostic model for glioma based on Heat Shock Proteins-associated genes (HSPGs). Using the Cancer Genome Atlas (TCGA) cohorts and the Chinese Glioma Genome Atlas (CGGA), we identified a signature of 4 HSPGs as an independent prognostic factor for glioma. The risk model demonstrated excellent performance in both training and validation sets. Additionally, we developed a nomogram incorporating clinical parameters and the HSPGs signature to enhance prognostic prediction. Immunoenrichment analysis revealed a correlation between the risk score and the immunosuppressive status of glioma. In the functional assays, HSPA5 was identified as a key participant in several critical biological processes associated with glioma. Silencing HSPA5 expression may lead to the inhibition of glioma cell proliferation, migration, invasion and resistance to apoptosis. These findings present a novel classification for glioma prognosis with enhanced accuracy and offer valuable insights into the potential use of HSPGs as prognostic indicators for gliomas.
- Open Access
- 27 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Rapid diagnosis of TERT promoter mutation using Terahertz absorption spectroscopy in glioblastoma
Glioblastoma (GBM) is a highly aggressive brain tumor with poor outcomes and limited treatment options. The telomerase reverse transcriptase (TERT) promoter mutation, one of the key biomarkers in GBM, is linked to tumor progression and prognosis. This study employed terahertz time-domain spectroscopy (THz-TDS) to analyze frozen GBM tissue sections, extracting six spectral features: absorption coefficient, dielectric loss factor, dielectric constant, extinction coefficient, refractive index, and dielectric loss tangent. LASSO regression was employed for feature selection, and then principal component analysis (PCA) was applied to minimize inter-feature correlations. A Random Forest classifier built on these features successfully predicted TERT mutation status, achieving an area under the receiver operating characteristic curve (AUC) of 0.908 in the validation set. Our findings demonstrate that THz spectroscopy, coupled with machine learning, can identify molecular differences associated with TERT mutations, supporting its potential as a rapid, intraoperative diagnostic tool for personalized GBM treatment. This approach could enhance surgical decision-making and optimize patient outcomes through precise, real-time molecular diagnostics.
- 27 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessRapid diagnosis of TERT promoter mutation using Terahertz absorption spectroscopy in glioblastoma
Glioblastoma (GBM) is a highly aggressive brain tumor with poor outcomes and limited treatment options. The telomerase reverse transcriptase (TERT) promoter mutation, one of the key biomarkers in GBM, is linked to tumor progression and prognosis. This study employed terahertz time-domain spectroscopy (THz-TDS) to analyze frozen GBM tissue sections, extracting six spectral features: absorption coefficient, dielectric loss factor, dielectric constant, extinction coefficient, refractive index, and dielectric loss tangent. LASSO regression was employed for feature selection, and then principal component analysis (PCA) was applied to minimize inter-feature correlations. A Random Forest classifier built on these features successfully predicted TERT mutation status, achieving an area under the receiver operating characteristic curve (AUC) of 0.908 in the validation set. Our findings demonstrate that THz spectroscopy, coupled with machine learning, can identify molecular differences associated with TERT mutations, supporting its potential as a rapid, intraoperative diagnostic tool for personalized GBM treatment. This approach could enhance surgical decision-making and optimize patient outcomes through precise, real-time molecular diagnostics.
- 14 May 2025
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 16 (6) , 2337-2350
Design of a polarization-insensitive terahertz metamaterial biosensor for glioma tissue identification
There is an urgent need to develop label-free, accurate detection techniques for gliomas due to the high aggressiveness and heterogeneity of glioma tissues. In this study, a polarization-insensitive terahertz metamaterial biosensor based on a quadruple rotationally symmetric superunit is proposed to address the issues of insufficient sensitivity and polarization-dependent interference associated with conventional metamaterials in terahertz spectroscopy. The structural parameters were optimized through theoretical modeling and electromagnetic simulations, leading to the design of C4-symmetric metamaterials with stable responses over a wide incidence angle range. These metamaterials effectively mitigate signal distortion caused by the random orientation of metamaterial placement during experiments. The experiments were conducted using a terahertz frequency-domain spectroscopy system (THz-FDS) to detect isolated glioma tissues. The results demonstrate that the sensor maintains polarization insensitivity across the full 0-360° range, significantly enhancing the contrast in dielectric properties between tumor and normal tissues. Furthermore, its resonance frequency shift exhibits a strong correlation with tissue thickness, increasing up to 26 µm, after which it stabilizes and no longer exhibits significant changes. This study confirms that polarization-insensitive metamaterials can overcome existing imaging limitations, reduce operator-induced human errors, and provide a novel, non-invasive detection solution for intraoperative boundary delineation and pathological diagnosis of gliomas, with strong potential for clinical translation.
- 14 May 2025
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 16 (6) , 2337-2350
Design of a polarization-insensitive terahertz metamaterial biosensor for glioma tissue identification
There is an urgent need to develop label-free, accurate detection techniques for gliomas due to the high aggressiveness and heterogeneity of glioma tissues. In this study, a polarization-insensitive terahertz metamaterial biosensor based on a quadruple rotationally symmetric superunit is proposed to address the issues of insufficient sensitivity and polarization-dependent interference associated with conventional metamaterials in terahertz spectroscopy. The structural parameters were optimized through theoretical modeling and electromagnetic simulations, leading to the design of C4-symmetric metamaterials with stable responses over a wide incidence angle range. These metamaterials effectively mitigate signal distortion caused by the random orientation of metamaterial placement during experiments. The experiments were conducted using a terahertz frequency-domain spectroscopy system (THz-FDS) to detect isolated glioma tissues. The results demonstrate that the sensor maintains polarization insensitivity across the full 0-360° range, significantly enhancing the contrast in dielectric properties between tumor and normal tissues. Furthermore, its resonance frequency shift exhibits a strong correlation with tissue thickness, increasing up to 26 µm, after which it stabilizes and no longer exhibits significant changes. This study confirms that polarization-insensitive metamaterials can overcome existing imaging limitations, reduce operator-induced human errors, and provide a novel, non-invasive detection solution for intraoperative boundary delineation and pathological diagnosis of gliomas, with strong potential for clinical translation.
- 30 March 2025
- Published by Elsevier in Analytical Biochemistry
- Vol. 702, 115850
A predictive model for MGMT promoter methylation status in glioblastoma based on terahertz spectral data
- 30 March 2025
- Published by Elsevier in Analytical Biochemistry
- Vol. 702, 115850
A predictive model for MGMT promoter methylation status in glioblastoma based on terahertz spectral data
- Open Access
- 28 November 2024
- Published by Taylor & Francis in Redox Report
- Vol. 29 (1) , 2433396
A reactive oxygen species-related signature predicts the prognosis and immunosuppressive microenvironment in gliomas
Intracellular redox homeostasis is crucial for a series of physiological processes. Reactive oxygen species (ROS) play important roles in redox processes. ROS can maintain cell reproduction and survival at moderate levels while promoting the initiation and progression of tumors at high levels. Based on a comprehensive analysis of ROS-related gene expression profiles, we established a gene signature associated with ROS to explore its influence on prognosis and immune microenvironment in gliomas. The ROS-related gene expression profile dichotomized patients into two groups with different clinicopathological features and prognoses. A 19-gene ROS-related signature was used to robustly predict prognosis in both training and validation datasets. Functional analysis indicated an association between ROS levels and the immune microenvironment. The expression of immune checkpoints and M2-type markers was upregulated in the high-risk group, which suggested the immunosuppressive function of ROS. ROS-related signature is an independent prognostic factor in gliomas and could potentially exert immunosuppressive effects on the tumor microenvironment.
- 28 November 2024
- Published by Taylor & Francis in Redox Report
- Vol. 29 (1) , 2433396
Open AccessA reactive oxygen species-related signature predicts the prognosis and immunosuppressive microenvironment in gliomas
Intracellular redox homeostasis is crucial for a series of physiological processes. Reactive oxygen species (ROS) play important roles in redox processes. ROS can maintain cell reproduction and survival at moderate levels while promoting the initiation and progression of tumors at high levels. Based on a comprehensive analysis of ROS-related gene expression profiles, we established a gene signature associated with ROS to explore its influence on prognosis and immune microenvironment in gliomas. The ROS-related gene expression profile dichotomized patients into two groups with different clinicopathological features and prognoses. A 19-gene ROS-related signature was used to robustly predict prognosis in both training and validation datasets. Functional analysis indicated an association between ROS levels and the immune microenvironment. The expression of immune checkpoints and M2-type markers was upregulated in the high-risk group, which suggested the immunosuppressive function of ROS. ROS-related signature is an independent prognostic factor in gliomas and could potentially exert immunosuppressive effects on the tumor microenvironment.